Navigation Links
Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
Date:6/13/2012

o guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Company:
Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... North American crystal oscillator market report defines and segments ... of revenue. This market was valued at $531.4 million ... by 2018, at a CAGR of 3.3% from 2013 ... North American crystal oscillator market report, to get an ... a glimpse of the segmentation of the market, and ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... PARIS and LAUSANNE, Switzerland, September 7 ... Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical,group of ... prescription drugs that,target unmet medical needs, announced today ... granted an exclusive worldwide license to develop,and commercialise ...
... manufacture hydroxyapatite (HA) could be used to make stronger, ... University of Birmingham this week (7-10 September) presented work ... University, Edinburgh. Using Serratia bacteria, the ... surfaces such as titanium alloy, polypropylene, porous glass and ...
... Sept. 6 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... biotechnology company,focused on researching, developing, manufacturing and marketing,biopharmaceutical ... of,shareholders of 3SBio Inc. will be held on ... No.3 A1, Road 10, Shenyang Economy & Technology ...
Cached Biology Technology:Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 2Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 3Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 4Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 53SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009 2
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... Rainmakers, Inc., an intellectual property holding company and advanced ... its "stealth" mode and is prepared to actively commercialize ... security offerings. , During the past four years, the ... develop and deploy a series of core--but expandable--technologies built ...
... up 45 percent of blood, normally take the shape of ... can sometimes deform into an asymmetrical slipper shape. A ... flow might be responsible for this deformation, as well as ... could help understand the mechanisms involved in arterial disease and ...
... CAMDEN Contrary to a national trend, more and ... major in math and science. Thanks to a $307,277 ... students in the sciences at RutgersCamden will receive unprecedented ... of their degrees. Through a new RutgersCamden program ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3NSF grant supports Rutgers-Camden program for science majors 2NSF grant supports Rutgers-Camden program for science majors 3
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Supplemental reagent for annexin V assay....
Biology Products: